In our present analysis, we draw the conclusion that EGFR-TKI adjuvant therapy can improve OS through including the new trials and updated OS data, thus providing a clear answer to the question of whether adjuvant therapy with EGFR-TKIs can lead to improved OS, which was not clearly answered in previous studies, and further emphasizing the role of EGFR-TKI adjuvant therapy in resected EGFR-mutant NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.